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Abstract: Polymer micelles with cross-linked ionic cores are shown here to improve 
the therapeutic performance of the platinum-containing anticancer compound cisplatin. 
Biodistribution, antitumor efficacy, and toxicity of cisplatin-loaded core cross-linked micelles 
of poly(ethylene glycol)-b-poly(methacrylic acid) were evaluated in a mouse ovarian cancer 
xenograft model. Cisplatin-loaded micelles demonstrated prolonged blood circulation, increased 
tumor accumulation, and reduced renal exposure. Improved antitumor response relative to free 
drug was seen in a mouse model. Toxicity studies with cisplatin-loaded micelles indicate a 
significantly improved safety profile and lack of renal abnormalities typical of free cisplatin 
treatment. Overall, the study supports the fundamental possibility of improving the potential 
of platinum therapy using polymer micelle-based drug delivery.
Keywords: cross-linked micelle, cisplatin, ovarian cancer, block ionomer complex, drug 
delivery
Introduction
The anticancer drug cisplatin (cis-diamminedichloro-platinum(II)) has revolutionized 
cancer management and continues to be in widespread clinical use, especially for 
management of tumors of the ovary, testes, and the head and neck.1,2 However, there 
are major limitations associated with cisplatin therapy. The majority of patients 
treated with cisplatin, with the exception of testicular cancer patients, experience only 
a partial antitumor response. Numerous systemic toxicities, such as neurotoxicity, 
ototoxicity, gastrointestinal disturbances, myelosuppression, and nephrotoxicity, 
prevent administration of higher cisplatin doses.3,4 The platinum drug has limited 
bioavailability due to its extensive binding to plasma proteins, spontaneous degradation 
in the bloodstream, and rapid clearance from the blood by glomerular excretion.5   
In addition, the emergence of acquired resistance to the drug further undermines its 
curative potential.6 Hence, improved pharmacological specificity for this indispensible 
anticancer agent is much needed.
Carrier-based delivery of platinum complexes has been investigated widely over the 
past decade and has demonstrated its ability to improve platinum drug performance.7,8 
Polymer micelles based on block ionomer complexes, in particular, are one such 
class of drug carriers that offers several key benefits over other colloidal systems for 
platinum drug delivery. These micelles, formed from copolymers containing an ionic 
block, can incorporate platinum complexes at an unusually high loading capacity 
(exceeding 30% by weight) through formation of polymer-metal complex cores.9,10 
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Their unique advantages also include ease of preparation 
and drug loading, and the ability to change block copolymer 
chemical composition, total molecular weight, and block 
length ratios, permitting precise control over micelle size 
and morphology.11 Furthermore, readily available functional 
groups in the ionic block can be used for simple and controlled 
core cross-linking, which is essential for their structural 
reinforcement and stability against disintegration.9 Fixation 
of micelle structures by cross-linking is of interest for a 
number of reasons. Conventional micelles exist in solution 
only above the copolymer critical micelle concentration 
(CMC; critical association concentration for block ionomer 
complexes) and are therefore subject to dissociation upon 
dilution; for example, upon administration into the blood 
stream.12 Cross-linked micelles (cl-micelles) are stable at 
concentrations below the CMC, can be lyophilized and 
redissolved as stable nanoparticles, and are less likely to 
collapse in response to environmental changes such as after 
systemic administration.12 As a result, cross-linking has the 
potential to increase circulation times and provide a means 
for temporal control over drug disposition. With respect 
to the material, these micelles differ from conventional 
micelles in behaving as nanogels, as they are composed of 
water-soluble polymer chains cross-linked within a nanoscale 
volume. Furthermore, these micelles have neither a dense 
core nor a defined surface and can undergo dramatic volume 
transitions upon environmental change. As a result, they 
have an unprecedented capacity for steric stabilization and 
decreased nonspecific interactions. The utility of such core 
cross-linked (cl)-micelles for encapsulation of anticancer 
drugs such as cisplatin9,13,14 and doxorubicin15,16 has been 
actively pursued by our group.
Here, we report the in vivo biodistribution, pharmacoki-
netics, antitumor effect, and toxicity of such cisplatin-loaded 
core cl-micelles (cisplatin/cl-micelles) in a mouse model, 
demonstrating the prolonged blood circulation, increased 
tumor accumulation, enhanced antitumor activity, and reduced 
toxicity of cisplatin/cl-micelles relative to free cisplatin.
Materials and methods
Materials
Poly(ethylene glycol)-b-poly(methacrylic acid) (PEG-b-
PMA) diblock copolymer (Mw/Mn = 1.45, block lengths 
of 170 units for PEG and 180 units for PMA) was from 
Polymer Source Inc (Montreal, QC, Canada). Cisplatin 
and platinum standard for inductively coupled plasma 
mass spectrometry (ICP-MS) calibration were from Acros 
Organics (Geel, Belgium). The chemicals 1,2-ethylenediamine 
(ED), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide 
hydrochloride (EDC), α-D-glucose (dextrose), and others 
were from Sigma-Aldrich (St Louis, MO). Cisplatin for 
injection (Platinol®) was from Bristol Laboratories (Princeton, 
NJ). Iridium chloride internal standard for ICP-MS was from 
Spex Certiprep (Metuchen, NJ). Double distilled nitric acid 
70% and hydrochloric acid 6 M were from GFS chemicals 
(Columbus, OH). Externally threaded 2 mL cryovials for 
plasma/tissue digestion were from Corning (Lowell, MA). 
Heparinized tubes for blood collection (Microtainer® tubes) 
were from BD (Franklin Lakes, NJ). A2780 human ovarian 
carcinoma cells were provided by Dr P Rogers (Institute of 
Cancer Research, University of Bristol, UK).
General procedure for synthesis  
of cl-micelles
The general procedure for synthesis of PEG-b-PMA 
cl-micelles has been described earlier.9 Briefly, PEG-b-
PMA/Ca2+ complexes were prepared by mixing an aqueous 
solution of PEG-b-PMA with a solution of CaCl2 at a molar 
ratio of [Ca2+]/[COO−] = 1.3. Chains were cross-linked 
overnight at room temperature using ED and EDC. Extent 
of cross-linking was targeted to 20% and was controlled by 
the ratio of amine functional groups of ED to carboxylic acid 
groups of polymer chains. After completion of the reaction, 
a 1.5 molar excess amount of ethylenediaminetetraacetic 
acid relative to Ca2+ was added and followed with extensive 
dialysis, first against 0.5% aqueous ammonia and then against 
distilled water to remove Ca2+ ions and by products of the 
cross-linking reaction.
Preparation of cisplatin/cl-micelles
Cl-micelles were mixed with cisplatin (1 mg/mL) at pH 9.0 
([cisplatin]/[COOH] = 0.5) followed by incubation at 37°C 
for 48 hours. Unbound cisplatin was removed by ultrafil-
tration using Centricon® Plus-20 centrifugal filter units 
(molecular weight cutoff 30,000 Da; Millipore, Billerica, 
MA). The resultant cisplatin/cl-micelle solution was stored 
in the dark at room temperature until use.
Particle characterization
Particles were characterized by dynamic light scattering, 
zeta (ζ)-potential, effective hydrodynamic diameters, and 
polydispersity indices as described previously.17
Animal facility and standard of care
Upon arrival, animals were placed in a facility accredited by the 
Association for Assessment and Accreditation of Laboratory 
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Animal Care. Food and reverse osmosis water were available 
ad libitum throughout the study. Euthanasia was performed by 
CO2 asphyxiation. Treatments were administered by tail vein 
injection. Drug amount was calculated based on the average 
animal body weight. All animal protocols were approved 
by the University of Nebraska Medical Center Institutional 
Animal Care and Use Committee.
Biodistribution of cisplatin/cl-micelles  
in mice
Four-week-old female athymic (Ncr-nu/nu) mice were 
purchased from the National Cancer Institute (Bethesda, 
MD) and quarantined for 7 days prior to tumor inoculation. 
Human ovarian tumor xenografts were initiated by inject-
ing A2780 cells (5 × 106 cells/site) subcutaneously into the 
flanks, one above each limb. When tumor size was approxi-
mately 200–300 mm3, animals were randomized based on 
tumor volume into 2 treatment groups, and given either free 
cisplatin or cisplatin/cl-micelles at an equivalent dose of 
7.5 mg-cisplatin/kg body weight through intravenous tail vein 
injection. Animals in groups of six (n = 6) were euthanized 
at each time point of 0, 5, and 40 minutes and 1, 6, 24, 48, 
and 72 hours, and blood was collected in heparinized vials 
through cardiac puncture. Animals were then perfused with 
about 30 mL saline. Lungs, liver, kidney, spleen and tumors 
were excised, washed with saline and frozen over dry ice 
before storage at −80°C. Blood was immediately centrifuged 
at 10,000 rpm for 15 minutes to obtain plasma, and frozen 
at −80°C prior to further analysis. The percentage of injected 
dose in plasma was calculated considering plasma volume 
in mice to be 45.6 mL/kg.18
Sample preparation and platinum 
measurement
Known weights of thawed tissue were decomposed by wet-
ashing in screw-capped vials with six volumes of concentrated 
nitric acid, overnight heating, and stirring at 65°C. An iridium 
internal standard was added prior to digestion. Platinum 
concentrations were read on a Varian ICP-MS (part no 
0010082601 [Walnut Creek, CA]; ICP-MS Expert software v 
2.1 b103 © 2006) using iridium correction. Calibration range 
for the assay was platinum 2–100 ng/mL with extrapolation to 
platinum 1000 ng/mL. Necessary dilutions were made if the 
platinum concentration exceeded the calibration range. Assay 
sensitivity was platinum 0.8 ng/mL, with inter- and intraday 
assay variability not exceeding 5%. However, the assay did 
not differentiate between micellar and nonmicellar platinum 
or between free and protein-bound platinum.
Pharmacokinetic analysis
Serum concentration versus time and tissue concentration 
versus time profiles were analyzed using noncompartmental 
analysis with WinNonlin 3.1 (Pharsight Corporation, Palo 
Alto, CA). The following parameters were determined: area 
under the curve (AUC), maximum platinum concentration 
(Cmax), time to obtain maximum platinum concentration 
(Tmax), total body clearance (Cl), terminal half-life of platinum 
(t1/2), steady-state volume of distribution (Vss), the apparent 
terminal elimination rate constant (Λ), and mean residence 
time (MRT). For serum, AUC from zero to infinity was used, 
whereas AUC up to 72 hours was used for tissues.
Antitumor activity
This was evaluated in female nude mice bearing subcutaneous 
A2780 cell ovarian xenografts. When the tumor size was 
approximately 100 mm3, animals were randomized based 
on tumor volume (three treatment groups, n = 6). Mice 
were administered free cisplatin or cisplatin/cl-micelles at 
an equivalent dose of cisplatin 4 mg/kg, or 5% dextrose 
solution through intravenous tail vein injection, a total of 
four times with each treatment at 4-day intervals. Animal 
body weight and tumor volume were monitored every second 
day. Tumor volume (V = 0.5 × L × W2) was estimated by   
measuring two orthogonal diameters (longer dimension: L and 
smaller dimension: W) of the tumor using electronic calipers. 
Animals were sacrificed when tumor volume exceeded 
3000 mm3, greatest tumor dimension exceeded 20 mm, tumor 
became necrotic, or when they exhibited a body weight loss 
of more than 20%. All other animals were sacrificed by 
day 25.
Toxicity analysis
Six-week-old female C57Bl/6 mice were purchased from 
Charles River Breeding Laboratories (Raleigh, NC), 
quarantined for 7 days, and randomized based on body 
weight into four groups (n = 10). Mice were administered 
either free cisplatin or cisplatin/cl-micelles at an equivalent 
dose of cisplatin 4 mg/kg, empty micelles at 2.5 mg/kg, or 
5% dextrose solution through intravenous tail vein injection,   
a total of four times with each treatment at 4-day intervals. 
Body weights were measured every day. Animals were 
monitored daily for stress.
For acute toxicity evaluation, five animals from each 
group were sacrificed on day 13, one day after completion of 
treatment, and the remaining five animals were sacrificed at 
day 28. Blood, kidneys, liver, spleen, brain, spinal cord, and 
bone were collected at necropsy. Kidneys, liver, and spleen 
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were weighed and fixed in buffered formalin. The other tis-
sues were placed immediately in buffered formalin. Blood 
was collected in heparinized tubes and analyzed for plasma 
concentrations of blood urea nitrogen (BUN), creatinine, 
alkaline phosphatase, aspartate aminotransferase (AST), and 
alanine aminotransferase (ALT) at the Nebraska Medical 
Center clinical laboratory using a UniCel® DxC 600 Syn-
chron® Clinical System (Beckman, CA).
Histopathology and image analysis
Fixed tissues were processed, sectioned, inserted into tissue 
cassettes, dehydrated in 70% ethanol overnight, and paraffin 
embedded (UNMC Tissue Sciences Facility, Omaha, NE). 
Serial 5 µm sections were stained with either hematoxylin 
and eosin (H&E) or by immunohistochemistry (IHC). 
For histopathological diagnosis, H&E-stained slides were 
examined by light microscopy and photomicrographs 
were taken using a Nikon camera mounted on a Nikon Eclipse 
600 microscope (both Nikon Instruments, Melville, NY) with 
Adobe Elements 3.0 software (Adobe Systems, San Jose, CA). 
For IHC detection of cl-micelles in tissues, rabbit monoclonal 
antibody to PEG (anti-PEG methoxy group; Epitomics, 
Burlingame, CA) was used. Polymer-based HRP-conjugated 
anti-rabbit Dako EnVision system (Dako, Glostrup, Denmark) 
was used for secondary detection with 3,3′-diaminobenzidine 
(Dako) as the chromogen followed by counterstaining with 
Mayer’s hematoxylin. Stained slides were analyzed using 
light microscopic observation and photomicrographs were 
obtained by Optronics (Goleta, CA) digital camera fixed 
to an Eclipse E800 (Nikon Instruments) using MagnaFire 
2.0 software (Olympus America, Melville, NY).
Flow cytometry
Female nude mice bearing subcutaneous A2780 ovarian xeno-
grafts of approximately 800 mm3 in size were randomized 
into three treatment groups (with three animals per group) 
and administered free cisplatin, cisplatin/cl-micelles (both 
at cisplatin 7.5 mg/kg equivalents), or empty cl-micelles 
(polymer 20 mg/kg corresponding to a polymer amount 
equivalent to cisplatin/cl-micelles treatment). Animals 
were sacrificed 24 hours post-treatment. Liver, spleen, and 
tumors were harvested, and a part of each was used for flow 
cytometric analysis.
For flow cytometry, tissue samples were processed 
as previously described.19 Isolated viable cells (1 × 106) 
were stained for murine macrophages with FITC-labeled 
monoclonal antibody against cell surface antigen CD14 
(eBioscience, San Diego, CA) and antibodies against PEG 
for cl-micelles (BD IntraSure kit, BD, San Jose, CA). 
Cells were analyzed using BD LSR II with BD FACS Diva 
software (BD Immunocytometry Systems, Mountain View, 
CA); 10,000 events were acquired in linear mode, gated to 
exclude debris and dead cells, and visualized in logarithmic 
mode. Appropriate isotype controls were used.
Statistics
For the antitumor study and toxicity studies, group means 
for tumor volume and body weights were evaluated using 
repeated measures analysis of variance with the Bonferroni 
post test. Survival was estimated using Kaplan–Meier analysis 
and compared using log-rank test. Platinum levels at various 
time points for biodistribution studies, blood chemistry 
markers for toxicity analysis, and tissue weights at sacrifice 
were compared using two-tailed Student’s t-test with unequal 
variance. P values less than 0.05 were considered significant. 
Analysis of variance with Bonferroni test and Kaplan–Meier 
analysis with log-rank test were performed using GraphPad 
Prism 5 (GraphPad Software, Inc, La Jolla, CA). Student’s 
t-test was performed using Microsoft® Excel 2007 (Microsoft 
Corporation, Redmond, WA).
Results
PEG-b-PMA cl-micelles represent hydrophilic nanogel-like 
structures with a swollen core of cross-linked PMA networks 
surrounded by a PEG shell. Their synthesis, characterization, 
and properties have been described earlier.9,17 Briefly, their 
hydrodynamic diameters range from 100 to 200 nm, have 
Table  1  Hemolytic  activity  of  cisplatin/cl-micelles  and  empty   
cl-micelles against human red blood cells
Treatment Concentration 
(μg/mL)
% hemolysis
Empty cl-micelles 40 0.00
120 0.00
400 0.08
Cisplatin/cl-micelles 60 0.00
170 0.00
500 0.02
Notes:  Whole  blood  from  a  single  healthy  female  volunteer  was  collected  in 
tubes containing Li-heparin, centrifuged at 800 g for 10 minutes, rinsed two times 
with phosphate-buffered saline (PBS), and resuspended in PBS at 37°C. Micelles 
were then added to the blood cell suspension to obtain designated concentrations 
and a final erythrocyte concentration of 108 cells/mL (PBS, pH 7.4). PBS and 1% 
Triton X-100 solutions added to the blood cells samples were used as negative and 
positive controls, respectively. The resulting suspensions were incubated at 37°C 
for 1 hour under agitation of 150 rpm, centrifuged at 800 × g (10 min) and analyzed 
for hemolysis in the supernatant using absorbance at 545 nm. The percentage of 
hemolysis was calculated as: Hemolysis (%) = (Asample – A0)/(A100 – A0) × 100%, where 
Asample is the sample absorbance, A0 and A100 are absorbance values corresponding to 
PBS control and to the cells completely lysed with 1% Triton X-100. Data are mean 
from two different samples with an internal set of duplicates.
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a narrow size distribution (polydispersity index , 0.1), 
and a net negative charge (ζ-potential from −20 mV 
to −30 mV). Cisplatin loading into cl-micelles involves a 
metal complex formation between PMA chains and cisplatin, 
and proceeds with a decrease in both size and ζ-potential.14 
Cisplatin/cl-micelles with a targeted cross-link density of 
20% (average size of about 110 nm, ζ-potential −12 mV , 
and loading capacity 30% w/w) were shown previously to be 
optimum for a drug-release profile consistent with desirable 
lower release rates in systemic circulation and higher rates in 
the tumor environment. The released cisplatin was shown to 
maintain its ability to form platinum-DNA adducts, although, 
due to its slow release from cl-micelles, the overall in vitro 
cytotoxicity of the system compared with the free drug is 
reduced.14 Neither empty nor cisplatin-loaded cl-micelles 
showed any hemolytic activity toward red blood cells, an 
essential prerequisite for their in vivo use (Table 1). Here we 
evaluate the in vivo distribution, pharmacokinetics, antitumor 
effect, and toxicity of cisplatin/cl-micelles in mice.
Pharmacokinetics and biodistribution  
of cisplatin/cl-micelles in mice
Biodistribution of cisplatin loaded into cl-polymer micelles 
after intravenous administration was determined by 
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Figure 1 Concentration–time profile of platinum in A2780 human ovarian cancer xenograft-bearing female nude mice. 
Notes: Platinum levels were measured following a single intravenous dose of cisplatin/cl-micelles () or cisplatin () at 7.5 mg cisplatin equivalents/kg body weight, in   
(A) plasma, (B) tumor, (C) kidney, (D) lung, (E) liver and (F) spleen. Values indicated are means ± standard error of the mean (n = 6), *P , 0.05.
Table  2 Pharmacokinetic  parameter  estimates  of  platinum  in 
plasma for cisplatin or cisplatin/cl-micelle-treated A2780 human 
ovarian cancer xenograft-bearing female nude micea
Parameter Cisplatin Cisplatin/cl-micelles
Cmax
b (µg/mL) 19.22 80.12
AUC (µg h/mL) 32.61 707.03
Cl (mL/h kg) 2.61 0.14
Vss (L/kg) 82.48 1.69
Λ 0.037 0.072
MRT (h) 31.63 12.37
Notes: aThe pharmacokinetic parameters were calculated using a noncompartment 
model  with  WinNonlin  program.  bCmax  represents  the  maximum  observed 
concentration  at  the  earliest  evaluated  time  point  of  5  min  post  dosage. 
Abbreviations: C max,  maximum  platinum  concentration;  AUC,  area  under  the 
curve; Cl, clearance; Vss, steady-state volume of distribution; Λ, apparent terminal 
elimination rate constant; MRT, mean residence time.
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measuring platinum concentrations in plasma and peripheral 
tissues at different time points up to 72 hours (Figure 1). 
Consistent with previous reports,20,21 free cisplatin 
disappeared rapidly from circulation, with only about 9% 
of the injected dose detectable in plasma 5 minutes after 
dosing. However, cisplatin/cl-micelles showed remarkably 
prolonged blood circulation, with more than 65% of 
the injected dosage retained 5 minutes after dosing and 
about 9% of the injected dose detectable 24 hours after 
dosing. Cisplatin and cisplatin/cl-micelle plasma platinum 
concentration versus time data was characterized by 
noncompartmental analysis (Table 2). Cisplatin/cl-micelle-
treated mice had a fourfold higher maximum observed 
platinum Cmax, as well as 20-fold higher plasma AUC. 
Both Vss and Cl were decreased by 48-fold and 18-fold, 
respectively, in the cisplatin/cl-micelle treatment group 
compared with the cisplatin treatment group.
Peak platinum levels were observed in each tissue 
within 1 hour of cisplatin treatment consistent with its 
rapid distribution, followed by a gradual decline (Figure 1). 
Tumor platinum levels after cisplatin/cl-micelle treatment 
peaked at 6 hours, more than fourfold higher than with free 
cisplatin treatment (P , 0.05) (Figure 1B), and continued to 
be consistently higher up to 72 hours. At 72 hours, the last 
point of evaluation, tumor platinum levels remained more 
than twofold higher (P , 0.05) with cisplatin/cl-micelle 
treatment. Furthermore, tumor platinum Cmax was higher 
with cisplatin/cl-micelle treatment compared with free 
cisplatin treatment (Table 3). Consistent with previously 
reported literature,22 the greater part of free cisplatin 
appears to be excreted by kidney (Figure 1C). Indeed, being 
the excretory organ for free cisplatin, kidneys showed a 
higher platinum concentration than any other organ at all 
evaluated time points. Platinum concentrations in kidneys 
obtained from cisplatin-treated mice were highest at 1 hour 
after administration and gradually decreased until the 
end of the study. In contrast, renal levels of platinum in 
cisplatin/cl-micelle-treated mice remained lower than those 
from cisplatin-treated mice up to 24 hours, then started 
to increase, and did not decline until the end of the study 
(Figure 1C). Therefore, the renal platinum AUC following 
cisplatin/cl-micelle treatment was not much different from 
that with cisplatin treatment, although the renal platinum 
Cmax was much reduced (Table 3). This higher platinum 
exposure in kidneys at the late phase likely represents the 
released drug, consistent with in vitro release study data14 
and the macromolecular nature of cisplatin/cl-micelles, 
which exceeds the renal filtration threshold. The liver 
and spleen, which are organs responsible for removing 
macromolecules from the bloodstream, showed a strong 
accumulation of cisplatin/cl-micelles (Figure 1E and F). 
While liver platinum levels peaked at about 6 hours after 
treatment and then gradually declined, spleen platinum 
levels continued to increase until the end of the study 
at 72 hours.
Antitumor activity of cisplatin/cl-micelles 
in mice
The in vivo antitumor efficacy was tested in mice   bearing 
A2780 human ovarian cancer xenografts (Figure 2). 
Changes in relative tumor volume and body weight are 
shown in   Figure 2A and B, respectively. Both cisplatin and 
cisplatin/cl-micelle treatments significantly decreased tumor 
burden (P , 0.05) compared with the control group. However, 
tumors in the animals treated with cisplatin/cl-micelles 
remained significantly smaller (P , 0.05) than in animals 
treated with free cisplatin between days 12 and 20. As a 
result, increased survival of the animals was observed in 
mice treated with cisplatin/cl-micelle compared with cisplatin 
alone (Figure 2C, P , 0.05). There was significant weight 
loss in the cisplatin treatment group compared with both the 
control and cisplatin/cl-micelle treatment groups (P , 0.05). 
In contrast, the cisplatin/cl-micelle treatment group showed 
no significant body weight loss compared with the control. 
Free cisplatin and the cisplatin/cl-micelles were injected at 
an equivalent dose of cisplatin 4 mg/kg, determined as the 
maximum tolerated dose corresponding to the treatment 
schedule (Figure 3).
Table 3 Pharmacokinetic parameter estimates in various tissues for cisplatin or cisplatin/cl-micelle-treated A2780 human ovarian 
cancer xenograft-bearing female nude mice
Parameter Kidney Spleen Lung Liver Tumor
Cis Cis/cl-micelles Cis Cis/cl-micelles Cis Cis/cl-micelles Cis Cis/cl-micelles Cis Cis/cl-micelles
Tmax (h) 0.1 72.0 1.0 12.0 0.1 12.0 0.3 1.0 0.1 6.0
Cmax (µg/g tissue) 15.2 6.9 1.5 235.1 1.9 5.3 5.4 49.6 2.5 3.2
AUC (µg h/g tissue) 267 372 68 12115 59 284 235 2291 54 170
Abbreviations: Cis, cisplatin; Tmax, time to reach Cmax; Cmax, maximum platinum concentration; AUC, area under the curve.
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Toxicity analysis
Body weight analysis
Figure 4 represents body weight changes in C57Bl/6 mice 
during the acute toxicity study at day 13 and day 28 
(Figure 4A). The mice treated with free cisplatin showed 
a significant decrease in body weight compared with the 
control group and to the cisplatin/cl-micelle treatment group 
(P , 0.001). On day 13, the cisplatin-treated group had 
.13% body weight loss compared with day 0, significantly 
different from either the cisplatin/cl-micelle group or con-
trols (P , 0.001). In contrast, mice treated with cisplatin/
cl-micelles showed no body weight loss although their 
weight gain was slower than the control group. This slower 
weight gain is likely due to the released cisplatin rather than 
the polymeric carrier itself, as animal weight change was 
not significantly different from that of control in the free 
cl-micelle treatment group.
For toxicity analysis until day 28, the animals were 
allowed to recover after the fourth treatment on day 12 
(Figure 4A). Animals in the empty cl-micelle treatment 
group and cisplatin/cl-micelle treatment group continued to 
gain weight, reaching an adult body weight not significantly 
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(C) Kaplan–Meier analysis of overall survival in: (1) control group, (2) cisplatin 
treatment group, and (3) cisplatin/cl-micelle treatment group.
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Figure 3 Relative changes in body weight in C57Bl/6 mice. 
Notes: (A) Cisplatin was injected intravenously every 4 days, four administrations 
in total, at a dose of 1 mg/kg (), 3 mg/kg (), and 5 mg/kg (). (B) Cisplatin-loaded 
cl-micelles were injected at identical treatment schedule, at a cisplatin equivalent 
dose of 3 mg/kg (), 5 mg/kg (), and 10 mg/kg (O). Dextrose 5% treatment () 
was used as the control. Data are mean ± standard error of the mean (n = 3). 
Maximum tolerated dose was assumed to be 4 mg/kg in both treatment groups 
since the animals lost .20% body weight in both groups at the 5 mg/kg dose but 
did not lose any weight at the 3 mg/kg dose. Cisplatin-loaded cl-micelle treatment at 
10 mg/kg resulted in toxic deaths in two animals. The remaining animals had .20% 
weight loss and were sacrificed by day 5.
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significantly less compared with the control treatment group 
(P , 0.001).
Blood chemistry and tissue weights
Plasma BUN, creatinine, alkaline phosphatase, AST, and 
ALT concentrations were measured at day 13 and day 28 
of the study (Figure 4B and Table 4). Additionally, liver, 
spleen, and kidney tissue weights obtained at sacrifice and 
normalized to animal body weight were compared across 
the treatment groups (Table 5). At day13, the free cisplatin 
treatment group had an approximate fourfold elevation 
of BUN levels, significantly different from controls and 
the cistplatin/cl-micelle treatment group (P , 0.05). This 
increase in BUN is indicative of renal toxicity and is 
consistent with previously reported literature.4 Mice treated 
with cisplatin/cl-micelles, however, showed no significant 
differences in BUN levels compared to controls. Despite 
much higher exposure of liver and spleen to cisplatin 
in the cisplatin/cl-micelle treatment group (indicated 
by pharmacokinetics and biodistribution), there was no 
significant change in hepatic toxicity markers of blood 
chemistry (Table 4), indicating no obvious toxicity to the 
liver. Similarly, tissue weight analysis indicated a significant 
difference in kidney to body weight ratio in the cisplatin 
treatment group compared with the control and cisplatin/
cl-micelle treatment groups (P , 0.05) (Table 5). No 
significant differences were found in tissue to body weight 
ratios in cisplatin/cl-micelle treatment groups compared 
with the controls. At day 28, even though the animal body 
weights in the cisplatin-treated group had recovered, blood 
chemistry analysis still indicated a twofold elevation in 
serum BUN levels, significantly different from the cisplatin/
cl-micelle treatment group and control (P , 0.001) 
(Figure 4B). Serum BUN levels from the cisplatin/
different from controls. Mice treated with free cisplatin 
showed .11% body weight loss by day 15 compared with 
their weight on day 0, but then started to recover and at day 
28 had an average body weight gain of approximately 3% 
compared with the start of treatment. However, this was still 
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Figure 4 Acute toxicity analysis in female C57Bl/6 mice. 
Notes: (A) Changes in body weight (n = 5) until day 13 and day 28 were measured 
following intravenous administration of cisplatin/cl-micelles () or cisplatin () at 
4 mg/kg. Vehicle control groups received empty micelles 2.5 mg/kg (∆) or 100 µL of 
5% dextrose (). Four administrations were given in total with each administration 
at every fourth day. (B) Plasma BUN concentrations (n = 3–5) at the end of day 
13 and day 28 of toxicity analysis. Treatment groups are: (1) control, (2) cisplatin 
treatment, (3) cisplatin/cl-micelle treatment, and (4) empty micelle treatment. Values 
indicated are means ± standard error of the mean. 
Abbreviation: BUN, blood urea nitrogen.
Table 4 Clinical chemistry parameters from female C57Bl/6 mice at day 13 and day 28 of toxicity analysis
Treatment Alk phos 
(U/L)
ALT 
(U/L)
AST 
(U/L)
BUN 
(mg/dL)
Creatinine 
(mg/dL)
Day 13
Control 117 ± 10   58 ± 17   69 ± 8  18 ± 2 a
Cisplatin 113 ± 16 a 115 ± 24b  75 ± 21b a
Cisplatin/cl-micelles 111 ± 27   43 ± 9   81 ± 12c  22 ± 4c a
Empty cl-micelles 128 ± 20   50 ± 9   59 ± 7c  18 ± 2c a
Day 28
Control 136 ± 12   85 ± 28 d 20 ± 0 0.32 ± 0.05
Cisplatin 131 ± 12 112 ± 45 d 43 ± 6b 0.38 ± 0.03b
Cisplatin/cl-micelles 128 ± 25   93 ± 20 d 21 ± 5 0.29 ± 0.03
Empty cl-micelles 143 ± 15 100 ± 43 d 23 ± 5 0.34 ± 0.06
Notes: P values less than 0.05 were set as the level of significance. Data were expressed as mean ± standard deviation. aThese parameters could not be estimated due to 
inadequate blood draw. bRepresents significant difference from controls. cRepresents significant difference from free cisplatin. dThese parameters could not be accurately 
measured due to hemolysis in samples at blood draw.
Abbreviations: Alk phos, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen.
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Table 5 Tissue weights at sacrifice from female C57Bl/6 mice at day 13 and day 28 of toxicity analysis
Treatment Liver/BW Spleen/BW Kidney/BW
Day 13
Control   0.0505 ± 0.0013   0.0040 ± 0.0006   0.0114 ± 0.0007
Cisplatin   0.0527 ± 0.0012   0.0028 ± 0.0003a   0.0145 ± 0.0010a
Cisplatin/cl-micelles   0.0500 ± 0.0030   0.0040 ± 0.0005   0.0116 ± 0.0005
Empty cl-micelles   0.0510 ± 0.0033   0.0040 ± 0.0009   0.0115 ± 0.0007
Day 28
Control   0.0471 ± 0.0041   0.0037 ± 0.0005   0.0117 ± 0.0006
Cisplatin   0.0542 ± 0.0025a   0.0040 ± 0.0007   0.0116 ± 0.0005
Cisplatin/cl-micelles   0.0461 ± 0.0048   0.0038 ± 0.0005   0.0119 ± 0.0007
Empty cl-micelles   0.0468 ± 0.0018   0.0036 ± 0.0004   0.0120 ± 0.0008
Notes: aRepresents significant difference from controls. P values less than 0.05 were set as the level of significance. Data were expressed as mean ± standard deviation. 
Abbreviation: BW, body weight.
cl-micelle treatment group continued to be normal, showing 
no long-term effects. The partial recovery in serum BUN 
levels in the cisplatin group reflects a reversible component 
of cisplatin-induced renal toxicity.3
Tissue histopathology
Light microscopic examination of H&E stained sections 
from day-13 sacrificed animals (Figure 5) indicated focal 
subcapsular tubular vacuolization and basophilia in kidneys 
from all animals in the cisplatin-treated group (Figure 5B). 
In some animals, individual tubular necrosis, collecting 
duct necrosis at the tip of the papilla, and decreased 
cellularity in the papilla were also observed. Bone marrow 
suppression was the most prominent observation as 
indicated by hematopoietic hypocellularity and increased 
amounts of intercellular material (Figure 5F). In contrast, 
no histopathological changes were observed in kidneys 
(Figure 5C and D) and bone marrow (Figure 5G and H) 
from animals in the cisplatin/cl-micelle-treated or in empty 
cl-micelles-treated groups compared with the control. 
Tissue sections from animals sacrificed at day 28 indicated 
partial recoveries in affected tissues (Figure 5J). Clusters of 
regenerating tubules were observed in the subcapsular region 
of the kidney cortex. However, some of the other pathological 
renal changes were not completely reversible at this time 
point as indicated by persistence of basophilic tubules related 
to continuing regeneration, and an interstitial lymphocytic, 
chronic inflammatory infiltrate. Bone marrow changes 
seen at day 13 returned to normal by day 28 (Figure 5N), 
indicating only an acute, reversible effect of cisplatin 
treatment. No histopathological changes were observed 
in analyzed tissues in the cisplatin/cl-micelle treatment 
group (Figure 5K and O). In addition, no histopathological 
changes were observed by light microscopic observation 
of the liver and spleen from mice in the cisplatin/cl-micelle 
group compared with the controls, despite much higher 
platinum accumulation in these tissues relative to free-drug 
treatment (Figure 6).
Distribution of polymer micelles in tissues was further 
analyzed by IHC (Figure 7). No accumulation of cl-micelles 
was found in either the cortex or tubular regions of the kidney 
(cisplatin/cl-micelles: Figure 7A and B; empty cl-micelles: 
Figure 7C and D). Consistent with biodistribution data, a 
significant accumulation of cl-micelles was observed in 
spleen and liver. Liver showed a homogeneous distribution 
of micelles (cisplatin/cl-micelles: Figure 7E and F; empty 
cl-micelles: Figure 7G and H). However, in spleen micelles 
were found largely in the red pulp region and were scarce to 
nonexistent in the white pulp region (cisplatin/cl-micelles: 
Figure 7I and J; empty cl-micelles: Figure 7K and L). 
Morphology of PEG-positive cells together with their tissue 
localization indicated that the majority of the cl-micelle 
uptake is by macrophages.
Flow cytometry
The nature of the cells involved in cisplatin/cl-micelle 
uptake was further investigated using flow cytometry. 
Cells isolated from the liver, spleen, and tumor 24 hours 
after treatment were stained using fluorescence-labeled 
antibodies against the PEG methoxy group of the block 
copolymer and mouse macrophage marker CD14. The 
relative population of CD14+ cells isolated from various 
tissues was similar amongst various treatment groups 
(Figure 8A). The majority of PEG+ cells (70%–80%) 
in spleen and liver also expressed CD14+ (Figure 8B). 
Together, these results were in accordance with IHC 
data discussed above, indicating macrophage capture of 
cisplatin/cl-micelles. Tumor tissue was found to have two 
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distinct populations of PEG+ cells. One of them (about 
40% of total count) was also CD14+ and represents 
cl-micelles taken up by macrophages associated with the 
tumor. The remainder of cl-micelles delivered to the tumor 
seems to be associated with tumor cells. Comparable 
results were observed for the empty cl-micelle treatment 
group (Figure 8C).
Discussion
Polymer micelles with a cross-linked ionic core repre-
sent functional drug carriers with several key structural 
features suitable for effective drug delivery. These are a 
cross-linked ionic core, a hydrophilic PEG shell, and a 
nanoscale size. Properties of the cl-micelles can be altered 
by varying the block ionomer structure, number of the 
cross-links, hydrophobicity of the cross-linker, and use of 
cross-linkers with ionizable groups.23 Therefore, a wide 
variety of cl-micelles with different sizes and charges can 
be synthesized from the same micellar template. Rapid 
caveolae-mediated internalization of these cl-micelles in 
epithelial cancer cells but not in tight junction forming 
normal epithelial cells was recently reported by our group, 
and indicates tumor specificity of these nanosystems.24 
Cisplatin, a well-known cancer chemotherapeutic agent, 
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Figure 5 Histopathological changes in kidney and bone marrow tissues from toxicity analysis in female C57Bl/6 mice. 
Notes: Light microscopy images of hematoxylin and eosin-stained kidney (A–D, day 13; I–L, day 28) and bone marrow (E–H, day 13; M–P, day 28) were taken at a 
magnification of 200× and 100× respectively. Tissue samples were collected at day 13 and day 28 following intravenous administration of cisplatin/cl-micelles or cisplatin 
at 4 mg/kg body weight. Vehicle control groups received 2.5 mg free micelles/kg body weight or 100 µL of 5% dextrose. Four administrations were given in total, each 
administration performed every fourth day.
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Figure 6 Light microscopy images (original magnification 100×) of hematoxylin and eosin-stained liver and spleen tissues from toxicity analysis in female C57Bl/6 mice.
Notes: No histopathological changes were observed in liver (A and B, day 13; E and F, day 28) and spleen (C and D, day 13; G and H, day 28) following administration 
of free cisplatin at a dose of 4 mg/kg, cisplatin-loaded cl-micelles at a cisplatin equivalent dose of 4 mg/kg, or empty micelles at 2.5 mg polymer/kg body weight. 
Treatment was administered by bolus intravenous tail vein injection (n = 5), four treatments in total, with each treatment at a 4-day interval. The animals were sacrificed 
using CO2 euthanasia on day 13 and day 28 for toxicity analysis. Hematoxylin and eosin staining was performed as described in materials and methods.
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Figure 7 Immunohistochemistry images of PEG stained tissues from acute toxicity analysis in female C57Bl/6 mice. 
Notes: No accumulation was observed in the kidney (magnification 200×) from either cisplatin-loaded (A, cortex; B, tubules) or empty micelles (C, cortex; D, tubules) 
treatment groups. Liver (E–F, cisplatin/cl-micelles; G–H, empty micelle) and spleen (I–J, cisplatin/cl-micelles; K–L, empty micelle) showed strong accumulation of micelles 
(magnification 200×/400×). Spleen shows accumulation of micelles only in the red pulp region.
was incorporated into the ionic core of micelles with 
remarkably high efficiency, where cross-linking stabilized 
the micelles against structural disintegration in aqueous 
dispersions and prevented premature release of the drug.9 
Under physiological conditions, due to the presence of 
abundant counter ions, the coordination bond between 
cisplatin and the carboxylate group of the polymer core is 
lost, allowing slow and sustained release of active platinum 
complexes.9 Interestingly, the structural determinants 
mentioned above allow a precise control of drug loading 
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capacity, loading efficiency, and release behavior of the 
encapsulated drug.14
Biodistribution and therapeutic effectiveness of cisplatin/
cl-micelles were compared with those of cisplatin in solu-
tion in nude mice bearing human ovarian carcinoma A2780 
  xenografts. Significantly prolonged circulation of cisplatin/
cl-micelles was observed relative to free drug. In addition, 
cisplatin/cl-micelles had a more than 20-fold higher plasma 
AUC and about 50-fold lower Vss compared with cisplatin, 
  indicating that cisplatin/cl-micelles are more localized in the 
plasma compartment. Free cisplatin was rapidly distributed 
to all major organs, with the kidney having the highest drug 
exposure compared with other organs at all evaluated time 
points. Nephrotoxicity of cisplatin was shown to be highly 
correlated with peak platinum concentration in kidney tissues 
rather than the organ AUC.25 Indeed, reduced platinum Cmax 
with cisplatin/cl-micelle treatment could ameliorate cisplatin-
induced toxicity. Free-drug treatment led to significant weight 
loss in animals, elevation of serum BUN levels, and histo-
pathologic evidence of renal tubular toxicity, whereas the 
micelle-drug treatment group had normal markers. While bone 
marrow suppression occurred only during the treatment phase 
and was reversed by stopping the drug treatment, renal 
changes were more extensive and sustained, with significant 
changes in serum BUN, creatinine, and   tissue histopathology, 
even at day 28 of the study. Reduced nephrotoxicity of 
cisplatin/cl-micelles is likely due to its macromolecular 
size coupled with slow release of the drug, which leads 
to a lower renal tubular drug exposure. Since the size of 
cisplatin/cl-micelle complexes (MW . 106 Da) is far above 
the renal filtration threshold (approximately 40–50 kDa for 
hydrophilic copolymers),26 the kidney may not allow   filtration 
of these complexes. Indeed, antibody against the PEG 
  methoxy group of copolymers failed to recognize any micelles 
in the renal tubules or cortex. This is a significant result 
considering renal toxicity is the most severe,   dose-limiting 
toxicity with cisplatin treatment.
A strong accumulation of cisplatin/cl-micelles was 
observed in liver and spleen. However, such accumulation 
did not lead to any toxic effects. Cisplatin/cl-micelle treated 
animals, even after multiple doses, had normal weight gain, 
no indication of stress, normal serum levels of markers 
of hepatic and renal toxicity, and no changes in tissue 
histopathology. IHC and flow cytometry analysis indicates 
that the PEG-positive cells in the liver and spleen were 
macrophages, consistent with the known reticuloendothelial 
capture of nanoparticles.27 The clearance of cisplatin/
cl-micelles from these tissues is expected to be largely 
through the hepatobiliary route, although renal elimination of 
released cisplatin and filterable particle fragments generated 
over time is also possible. Biliary clearance was indeed 
shown to be the dominant route for elimination of silica 
nanoparticles of similar size and negative ζ-potential.28,29 It 
is quite likely that cisplatin/cl-micelles carrying macrophages 
will undergo several rounds of apoptotic cell and recapture 
of apoptotic bodies by surrounding macrophages before any 
significant elimination takes place. Therefore, clearance is 
expected to be slow and is consistent with our data indicating 
a significantly reduced PEG staining in liver and spleen tissue 
80
A
B
C
Cisplatin
Cl-micelles/cisplatin
Cl-micelles
CD14+
CD14+/PEG+
CD14+ cells in treatment groups
Cisplatin/cl-micelle treatment
Empty cl-micelle treatment
60
40
20
0
80
60
40
20
0
80
60
40
20
0
Spleen
P
o
s
i
t
i
v
e
 
c
e
l
l
s
,
 
%
P
o
s
i
t
i
v
e
 
c
e
l
l
s
,
 
%
P
o
s
i
t
i
v
e
 
c
e
l
l
s
,
 
%
Liver Tumor
Spleen Liver Tumor
Spleen Liver Tumor
Figure 8 Uptake of cisplatin/cl-micelles by macrophages. 
Notes: Female nude mice (n = 3) bearing A2780 ovarian cancer xenografts (approximately 
800  mm3),  administered  a  single  intravenous  tail  vein  injection  of  free  cisplatin  or 
cisplatin/cl-micelles (7.5 mg/kg), or empty micelles (20 mg polymer/kg body weight) 
were sacrificed 24 hours post-treatment and liver, spleen, and tumors were harvested 
for flow cytometric analysis. Staining was performed with anti-CD14 antibody and anti-
PEG antibody as described in material and methods. (A) Relative population of CD14 
positive cells amongst the treatment groups was similar. (B) and (C), majority of the 
PEG positive cells in the micelle treatment group liver and spleen costained for mouse 
CD14 (70%–80%), indicating macrophage uptake of micelles in these organs. Tumor had 
two distinct populations of cells with about 30%–40% of PEG positive cells costaining for 
CD14 while the remaining associated with other tumor cells.
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sections from day 28 toxicity analysis relative to respective 
day 13 tissue sections (Figure 9). This might also explain the 
lack of toxicity to the hepatocytes or spleen since cisplatin/
cl-micelles are sequestered by the macrophages.
In spleen, the micelles were localized predominantly in 
the red pulp with little to no staining in the lymphoid region. 
Free cisplatin treatment has previously been reported to 
have a noteworthy effect on immunological function due 
to its ability to reduce lymphocytes in the thymus and the 
spleen,30 with changes in splenic white pulp being the most 
significant.31 Indeed, analysis of tissue weights at the end of 
the toxicity study indicated a significant decrease in overall 
spleen weight and the spleen to body weight ratio in the 
cisplatin-treated group, whereas cisplatin/cl-micelle-treated 
animals had normal spleen weights (Table 5). Absence of 
cisplatin/cl-micelles from lymphoid regions of white pulp 
may thus limit free-drug exposure to these follicles. Given 
the role of a healthy immune system in cancer growth and 
treatment, these results may be of significance but require 
further investigation.
Prolonged circulation of cisplatin incorporated into 
cl-micelles also facilitated substantial tumor targeting and 
led to increased drug level in the tumor relative to free 
cisplatin treatment. Since our ICP-MS method for platinum 
measurement did not differentiate between micellar and 
nonmicellar platinum, the observed increased tumor platinum 
levels and tumor platinum AUC likely represents the sum of 
both the released and polymer-bound drug. Although our 
previous work has shown rapid and selective cellular uptake 
of these micelles in vitro by neoplastic cells,24 it can still be 
envisaged that the cisplatin/cl-micelles partially reside in the 
tumor extracellular space. This compartment can serve as an 
additional depot from which platinum complexes are slowly 
released and can be taken up by the surrounding tumor cells. 
AB
CD
Liver, day 13 Liver, day 28
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Figure 9 Immunofluorescence images (original magnification 200×) of liver and spleen tissues from toxicity analysis in female C57Bl/6 mice. 
Notes: Slide mounted sections (5 µm) of liver (A, day13; B, day 28) and spleen (C, day 13; D, day 28) following administration of cisplatin-loaded cl-micelles at a cisplatin 
equivalent dose of 4 mg/kg were stained for PEG (anti-PEG antibody, green) and nuclei (4′,6-diamidino-2-phenylindole, blue). Significant decrease in PEG staining in day 28 
tissues was seen relative to corresponding day 13 tissues. Treatment was administered by bolus intravenous tail vein injection (n = 5), four treatments in total, with each 
treatment at a 4-day interval. The animals were sacrificed using CO2 euthanasia on day 13 and day 28 for toxicity analysis. 
Abbreviation: PEG, poly(ethylene glycol).
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Overall, the sequestration of cisplatin/cl-micelles in tumor 
tissue followed by prolonged release of the active platinum 
species appears to translate into an enhanced anticancer 
effect of this micellar drug formulation. Indeed, a greater 
suppression of tumor growth and increased lifespan of the 
animals were observed during the post-treatment period in 
cisplatin/cl-micelle group. The extent of tumor inhibition 
relative to free cisplatin observed in this study is comparable 
or better than what has been reported for other micellar and 
nanoparticulate systems of similar size and charge, despite 
a considerably more aggressive tumor model employed in 
our investigations. In particular, the tumor size increased by 
30–35-fold in 14 days in the control groups of animals bearing 
A2780 xenografts. In contrast, a subcutaneous KB epidermal 
carcinoma tumor model used in the study by Xue et al32 was 
characterized by significantly slower growth rate (the tumor 
size in control animals increased only by approximately 
14-fold in 15 days). Yet, no improvement in antitumor activity 
of ∼110 nm PEG-poly (N-amino acidyl)-aspartamide-
cisplatin micelles relative to free cisplatin was reported. 
Recent work by Paraskar et al33 also utilized aggressive 
cancer models (subcutaneous Lewis lung carcinoma and 4T1 
breast cancer xenografts) to evaluate the antitumor activity 
of 80–140 nm cisplatin-loaded poly-isobutylene-maleic 
acid nanoparticles. However, no improvement in antitumor 
activity relative to equidose free cisplatin was observed. In 
this regard, carrier size may be a critical parameter directly 
affecting the enhanced permeability and retention-mediated 
tumor accumulation, tumor penetration and, hence, the 
antitumor activity of a drug delivery system. A recent 
report by Kataoka and colleagues34 indicates that while the 
widely used ∼100 nm drug-containing polymeric carriers 
are effective in treating highly permeable tumors, smaller 
sized particles may be needed to improve the therapeutic 
performance against tumors with poor permeability. In view 
of these reported data, further optimization and evaluation 
of our formulations are necessary, including testing tumor 
permeability. Studies investigating the fabrication of sub-
100 nm cl-micelles and a comprehensive analysis of the 
influence of the size of such materials on their drug delivery 
properties are underway. These structure–activity relationship 
data will greatly benefit design of future nanomaterials for 
effective platinum drug delivery.
Conclusion
This study evaluated cisplatin-loaded cross-linked polymer 
micelles in mice and demonstrated the improved therapeutic 
potential of cisplatin upon incorporation into the micelles. 
Cisplatin-loaded cl-micelles exhibited significantly pro-
longed blood circulation, higher tumor accumulation, and 
reduced kidney exposure relative to the free drug. As a 
result, the micellar cisplatin formulation showed an improved 
antitumor activity in a mouse ovarian tumor xenograft model 
without any indication of systemic toxicity. Thus, our find-
ings of markedly reduced toxicity of the cl-micelle-bound 
cisplatin in combination with improved pharmacokinetics 
and enhanced antitumor efficacy indicate that cisplatin/
cl-micelles may have considerable benefits in clinical applica-
tions as an effective treatment modality in cancer and war-
rant further optimization for delivery of platinum-containing 
therapeutics.
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